Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for IOVA

Stock NameIovance Biotherapeutics Inc
TickerIOVA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS4622601007
LEI2549002L8WT2ACU5Q878

Show aggregate IOVA holdings

News associated with IOVA

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.62 and traded as low as $2.19. Iovance Biotherapeutics shares last traded at $2.22, with a volume of 9,006,027 shares trading hands. Analyst Upgrades and Downgrades A number […] - 2025-09-18 04:49:17
After Hours Most Active for Aug 21, 2025 : NVDA, AMZN, LCID, AAPL, IOVA, AVGO
The NASDAQ 100 After Hours Indicator is down -18.44 to 23,124.14. The total After hours volume is currently 97,306,839 shares traded.The following are the most active stocks for the after hours session: NVIDIA Corporation (NVDA) is -0.07 at $174.91, with 4,892,038 shares traded. - 2025-08-21 17:24:54
HC Wainwright Reiterates Buy Rating for Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $20.00 price target on the biotechnology company’s stock. Other equities analysts have also recently issued research reports about the stock. Truist Financial cut […] - 2025-08-21 04:24:45
Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug
(RTTNews) - PainReform Ltd.'s (PRFX) solar energy business unit, developing next-generation AI-driven solar analytics, DeepSolar, has been accepted into the NVIDIA Connect Program. This gives DeepSolar access to NVIDIA's AI frameworks, development tools, and engineering support t - 2025-08-19 10:36:15
Pre-Market Most Active for Aug 19, 2025 : OPEN, INTC, IOVA, TGNA, TSLL, JNJ, SQQQ, WMT, NVO, NVDA, XPEV, NIO
The NASDAQ 100 Pre-Market Indicator is down -14.36 to 23,699.4. The total Pre-Market volume is currently 178,882,121 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.38 at $4.16, with 20,195,663 shares trad - 2025-08-19 09:29:56
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Chicago Partners Investment Group LLC
Chicago Partners Investment Group LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 97.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,626 shares of the biotechnology company’s stock after purchasing an additional 20,067 shares […] - 2025-08-13 04:56:58
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5% After Analyst Downgrade
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares dropped 5% during mid-day trading on Monday after Wells Fargo & Company lowered their price target on the stock from $18.00 to $14.00. Wells Fargo & Company currently has an overweight rating on the stock. Iovance Biotherapeutics traded as low as $2.02 and last traded at […] - 2025-08-12 02:18:51
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Avantax Advisory Services Inc.
Avantax Advisory Services Inc. raised its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 39.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,560 shares of the biotechnology company’s stock after acquiring an additional 5,205 shares during the […] - 2025-08-11 06:04:48
XTX Topco Ltd Takes Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
XTX Topco Ltd bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 181,832 shares of the biotechnology company’s stock, valued at approximately $606,000. A number of other large […] - 2025-08-06 05:20:52
TD Asset Management Inc Sells 171,200 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
TD Asset Management Inc lowered its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 55.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 139,878 shares of the biotechnology company’s stock after selling 171,200 shares during the period. TD Asset Management Inc’s holdings in […] - 2025-08-05 05:32:52
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Key PointsIovance launched its first product, called Amtagvi, last year. - 2025-07-29 04:29:00
Iovance Biotherapeutics Target of Unusually High Options Trading (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the target of some unusual options trading on Wednesday. Traders bought 53,902 call options on the company. This is an increase of approximately 956% compared to the average volume of 5,106 call options. Institutional Trading of Iovance Biotherapeutics A number of hedge funds and other institutional […] - 2025-07-25 04:24:55
Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Affirm Holdings Inc (Symbol: AFRM), where a total of 29,448 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about - 2025-07-23 16:27:11
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Rating Lowered by The Goldman Sachs Group
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was downgraded by research analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research note issued on Tuesday, MarketBeat reports. A number of other research analysts have also recently weighed in on the stock. Chardan Capital cut their price objective on […] - 2025-07-17 05:14:57
Iovance Biotherapeutics (NASDAQ:IOVA) Downgraded to Sell Rating by The Goldman Sachs Group
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was downgraded by The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday, MarketBeat reports. Several other research analysts have also issued reports on IOVA. JMP Securities reiterated a “market perform” rating on shares of Iovance Biotherapeutics in a […] - 2025-07-17 05:14:57
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Lowered to “Sell” at The Goldman Sachs Group
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a report issued on Tuesday, MarketBeat.com reports. Several other analysts also recently commented on IOVA. UBS Group downgraded Iovance Biotherapeutics from a “buy” rating to a “neutral” rating and […] - 2025-07-17 05:14:57
Cambridge Investment Research Advisors Inc. Buys 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Cambridge Investment Research Advisors Inc. lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 12.9% in the 1st quarter, Holdings Channel reports. The institutional investor owned 45,877 shares of the biotechnology company’s stock after acquiring an additional 5,237 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Iovance Biotherapeutics were […] - 2025-07-15 04:17:30
After Hours Most Active for Jun 6, 2025 : IOVA, NVDA, INTC, ACHR, AAL, CSX, AAPL, NKE, PCG, BAC, MRK, PFE
The NASDAQ 100 After Hours Indicator is up 14.86 to 21,776.65. The total After hours volume is currently 96,255,289 shares traded.The following are the most active stocks for the after hours session: Iovance Biotherapeutics, Inc. (IOVA) is +0.02 at $2.07, with 5,435,272 shares t - 2025-06-06 17:24:57
Ameriprise Financial Inc. Has $463,000 Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Ameriprise Financial Inc. lessened its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 88.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 62,548 shares of the biotechnology company’s stock after selling 494,986 shares during the period. Ameriprise Financial Inc.’s holdings in Iovance Biotherapeutics […] - 2025-06-05 04:22:52
Captrust Financial Advisors Cuts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Captrust Financial Advisors lowered its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 42.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,738 shares of the biotechnology company’s stock after selling 20,868 shares during the period. Captrust Financial Advisors’ […] - 2025-05-23 04:47:02
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Resilient and growing. Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of what's happening with the economy. And with elderly populations increasing in many countries (including the U.S.), the demand for he - 2025-05-21 05:48:00
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Lowered to “Neutral” at UBS Group
UBS Group lowered shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a buy rating to a neutral rating in a report issued on Friday morning, Marketbeat.com reports. UBS Group currently has $2.00 price target on the biotechnology company’s stock, down from their prior price target of $17.00. Other equities research analysts also recently issued […] - 2025-05-19 02:46:52
Is This Beaten-Down Stock a Buy Near Its 52-Week Low?
Penny stocks -- companies with shares trading at around $5 or even less apiece -- usually carry above-average risk. However, there may be hidden gems among them: companies with attractive prospects that continue to be ignored by most investors. Identifying those penny stocks with - 2025-05-15 06:14:00
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.4% Following Analyst Downgrade
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price fell 5.4% during mid-day trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $16.00 to $8.00. The Goldman Sachs Group currently has a buy rating on the stock. Iovance Biotherapeutics traded as low as $1.85 and last traded […] - 2025-05-15 02:39:11
Iovance Biotherapeutics (NASDAQ:IOVA) Downgraded by Truist Financial to Hold
Truist Financial cut shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday morning, MarketBeat.com reports. A number of other equities research analysts also recently weighed in on the company. Chardan Capital lowered their price target on Iovance Biotherapeutics from […] - 2025-05-13 02:56:46
Pre-Market Most Active for May 9, 2025 : TSLL, SQQQ, TQQQ, QBTS, IOVA, WOLF, NVDA, IBIT, DNB, UMC, HIMS, AEG
The NASDAQ 100 Pre-Market Indicator is up 91.45 to 20,155.02. The total Pre-Market volume is currently 99,990,466 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.2 at $10.57, with 10,864,676 share - 2025-05-09 09:28:55
My 3 Favorite Stocks to Buy Right Now
Veteran investors know that the market's recent weakness is more of an opportunity than an omen. Sure, stocks may not have hit their ultimate bottom just yet. They're arguably closer to it than not, though. And five years from now, you won't care if you stepped in at the exact lo - 2025-05-06 04:15:00
First Trust Advisors LP Invests $2.40 Million in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
First Trust Advisors LP acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 324,246 shares of the biotechnology company’s stock, valued at approximately $2,399,000. A number of other institutional investors also […] - 2025-05-05 05:10:51
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Lessened by CANADA LIFE ASSURANCE Co
CANADA LIFE ASSURANCE Co cut its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 5.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,265 shares of the biotechnology company’s stock after selling 3,484 shares during the period. CANADA LIFE ASSURANCE Co’s holdings […] - 2025-05-01 05:38:58
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stake Raised by Invesco Ltd.
Invesco Ltd. lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 221,928 shares of the biotechnology company’s stock after acquiring an additional 4,967 shares during the quarter. Invesco Ltd.’s holdings in Iovance Biotherapeutics were worth $1,642,000 at the end of the most […] - 2025-04-30 04:46:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) IOVA holdings

DateNumber of IOVA Shares HeldBase Market Value of IOVA SharesLocal Market Value of IOVA SharesChange in IOVA Shares HeldChange in IOVA Base ValueCurrent Price per IOVA Share HeldPrevious Price per IOVA Share Held
2025-11-11 (Tuesday)227,854USD 603,813IOVA holding increased by 63799USD 603,8130USD 63,799 USD 2.65 USD 2.37
2025-11-10 (Monday)227,854IOVA holding increased by 589USD 540,014IOVA holding increased by 17304USD 540,014589USD 17,304 USD 2.37 USD 2.3
2025-11-07 (Friday)227,265IOVA holding increased by 592USD 522,710IOVA holding decreased by -905USD 522,710592USD -905 USD 2.3 USD 2.31
2025-11-06 (Thursday)226,673USD 523,615IOVA holding increased by 113337USD 523,6150USD 113,337 USD 2.31 USD 1.81
2025-11-05 (Wednesday)226,673USD 410,278IOVA holding decreased by -2267USD 410,2780USD -2,267 USD 1.81 USD 1.82
2025-11-04 (Tuesday)226,673IOVA holding increased by 594USD 412,545IOVA holding decreased by -28309USD 412,545594USD -28,309 USD 1.82 USD 1.95
2025-11-03 (Monday)226,079USD 440,854IOVA holding decreased by -4522USD 440,8540USD -4,522 USD 1.95 USD 1.97
2025-10-31 (Friday)226,079USD 445,376IOVA holding increased by 4522USD 445,3760USD 4,522 USD 1.97 USD 1.95
2025-10-30 (Thursday)226,079IOVA holding increased by 2970USD 440,854IOVA holding decreased by -5364USD 440,8542,970USD -5,364 USD 1.95 USD 2
2025-10-29 (Wednesday)223,109IOVA holding increased by 1188USD 446,218IOVA holding decreased by -39789USD 446,2181,188USD -39,789 USD 2 USD 2.19
2025-10-28 (Tuesday)221,921USD 486,007IOVA holding decreased by -26631USD 486,0070USD -26,631 USD 2.19 USD 2.31
2025-10-27 (Monday)221,921USD 512,638IOVA holding increased by 13316USD 512,6380USD 13,316 USD 2.31 USD 2.25
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of IOVA by Blackrock for IE00BYXG2H39

Show aggregate share trades of IOVA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY5892.6002.350 2.375USD 1,399 4.27
2025-11-07BUY592 2.300* 4.28
2025-11-04BUY5941.9301.805 1.817USD 1,080 4.31
2025-10-30BUY2,9702.0701.935 1.948USD 5,787 4.35
2025-10-29BUY1,1882.0002.170 2.153USD 2,558 4.36
2025-10-22SELL-2,3602.1502.250 2.240USD -5,286 4.42 Profit of 5,148 on sale
2025-10-20BUY1,1802.3202.410 2.401USD 2,833 4.44
2025-10-17BUY2,9452.1802.240 2.234USD 6,579 4.46
2025-10-15BUY4,6802.2402.270 2.267USD 10,610 4.47
2025-10-03BUY4,1582.3402.350 2.349USD 9,767 4.49
2025-10-02BUY5942.2502.280 2.277USD 1,353 4.51
2025-09-30BUY1,1862.1702.250 2.242USD 2,659 4.53
2025-09-26BUY1,1882.1102.110 2.110USD 2,507 4.56
2025-09-25BUY1,1882.0202.090 2.083USD 2,475 4.58
2025-09-24BUY22.1202.140 2.138USD 4 4.59
2025-09-18BUY5982.2002.340 2.326USD 1,391 4.60
2025-09-17BUY1,7972.2202.350 2.337USD 4,200 4.62
2025-08-20SELL-2,3602.5302.680 2.665USD -6,289 4.67 Profit of 4,734 on sale
2025-07-30BUY2,3442.6702.980 2.949USD 6,912 4.75
2025-07-17SELL-1,1762.3402.500 2.484USD -2,921 4.86 Profit of 2,795 on sale
2025-07-11SELL-4,7441.8701.930 1.924USD -9,127 4.94 Profit of 14,300 on sale
2025-07-07BUY1,7821.7001.800 1.790USD 3,190 5.02
2025-07-02BUY32,6701.7501.800 1.795USD 58,643 5.07
2025-06-20BUY13,1011.9802.090 2.079USD 27,237 5.09
2025-06-11BUY1,0982.2402.430 2.411USD 2,647 5.25
2025-06-10BUY1,1002.3802.470 2.461USD 2,707 5.27
2025-06-04SELL-5541.8301.870 1.866USD -1,034 5.37 Profit of 1,943 on sale
2025-04-23BUY5433.1903.430 3.406USD 1,849 6.28
2025-04-10SELL-4,3363.0603.160 3.150USD -13,658 6.59 Profit of 14,927 on sale
2025-04-08SELL-5422.8503.200 3.165USD -1,715 6.67 Profit of 1,902 on sale
2025-04-07SELL-5423.0303.190 3.174USD -1,720 6.72 Profit of 1,920 on sale
2025-04-04SELL-2,7203.0003.200 3.180USD -8,650 6.76 Profit of 9,737 on sale
2025-04-01BUY2,2443.2503.350 3.340USD 7,495 6.84
2025-03-31SELL-1,6353.3303.420 3.411USD -5,577 6.88 Profit of 5,678 on sale
2025-03-21BUY17,9893.5403.580 3.576USD 64,329 7.15
2025-03-14SELL-7,8243.5903.620 3.617USD -28,299 7.40 Profit of 29,575 on sale
2025-03-07SELL-9723.7503.800 3.795USD -3,689 7.67 Profit of 3,770 on sale
2025-03-04SELL-4863.9203.960 3.956USD -1,923 7.85 Profit of 1,894 on sale
2025-02-25BUY9685.3405.590 5.565USD 5,387 8.11
2025-02-19SELL-4825.6505.730 5.722USD -2,758 8.30 Profit of 1,240 on sale
2025-02-13BUY1,4435.3405.420 5.412USD 7,810 8.52
2025-02-12BUY4825.3405.430 5.421USD 2,613 8.58
2025-02-11BUY1,9245.2905.340 5.335USD 10,265 8.65
2024-12-30SELL-16,1997.1707.340 7.323USD -118,625 9.78 Profit of 39,857 on sale
2024-11-18SELL-7,8338.4308.650 8.628USD -67,583 10.83 Profit of 17,226 on sale
2024-11-08SELL-52210.59010.800 10.779USD -5,627 10.93 Profit of 77 on sale
2024-10-21SELL-5239.92010.180 10.154USD -5,311 0.00 Loss of -5,311 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of IOVA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-193,532,2346,4867,668,98346.1%
2025-09-182,284,7534,8165,499,98341.5%
2025-09-171,925,5018584,834,76639.8%
2025-09-161,602,5143,0015,745,09427.9%
2025-09-151,315,14203,744,72835.1%
2025-09-121,553,88505,376,81828.9%
2025-09-111,444,53429,2005,013,70128.8%
2025-09-102,044,82806,227,12832.8%
2025-09-092,298,7972,6626,167,90937.3%
2025-09-081,918,02415,763,19833.3%
2025-09-052,591,0129,1739,480,15727.3%
2025-09-041,500,39413,8104,107,38136.5%
2025-09-031,378,12804,349,26731.7%
2025-09-021,666,7052,1675,347,65931.2%
2025-08-291,159,1715,7133,980,99429.1%
2025-08-282,392,9702,5947,349,54432.6%
2025-08-271,280,6592365,717,98622.4%
2025-08-261,640,4881,3735,239,06131.3%
2025-08-251,887,8975,0247,003,25727.0%
2025-08-221,881,1232,0356,305,06829.8%
2025-08-212,014,40612,6006,384,63831.6%
2025-08-201,275,7551,7805,830,13821.9%
2025-08-197,448,38215,06014,553,52051.2%
2025-08-181,267,2133,6664,514,17728.1%
2025-08-151,712,99027,7854,919,18834.8%
2025-08-142,320,73625,1016,194,76337.5%
2025-08-133,315,3822,6458,468,00039.2%
2025-08-123,404,86308,950,84138.0%
2025-08-113,292,404466,1618,339,26139.5%
2025-08-0811,368,387839,07722,629,74050.2%
2025-08-073,657,1256229,790,53537.4%
2025-08-062,230,64606,811,61932.7%
2025-08-051,376,6181,5404,840,45828.4%
2025-08-042,606,7406,7246,273,53441.6%
2025-08-013,458,0133848,472,96440.8%
2025-07-312,782,193188,8837,020,87739.6%
2025-07-304,313,14399,90010,922,39539.5%
2025-07-292,439,0682,4008,572,48128.5%
2025-07-285,144,28720,69311,611,93544.3%
2025-07-254,787,166587,76813,516,49535.4%
2025-07-2410,773,627688,61222,380,07048.1%
2025-07-2333,356,596146,10754,914,89560.7%
2025-07-2212,195,98930,40224,964,95348.9%
2025-07-213,771,67034,43511,100,07634.0%
2025-07-183,360,31614,1768,564,86339.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.